2019 Analyst & Investor Day Bioinformatics Building the best suite of content-driven analytics Jonathan Sheldon Senior Vice President, Head of Bioinformatics Business Area Sample to Insight
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate statements. All statements other than statements of historical fact are, or may be deemed to be (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, provide additional insight on performance. In this presentation, adjusted results include adjusted as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash statements are based on current expectations of future events. If underlying assumptions prove flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered inaccurate or unknown risks or uncertainties materialize, actual results could vary materially in addition to reported results prepared in accordance with GAAP, but should not be considered from our own expectations and projections. Some of the factors that could cause actual results as a substitute. QIAGEN believes certain items should be excluded from adjusted results when to differ include, but are not limited, to the following: general industry conditions and competition; they are outside of its ongoing core operations, vary significantly from period to period, or affect risks associated with managing growth and international operations (including the effects of the comparability of results with its competitors and its own prior periods. Please see the currency fluctuations, regulatory processes and dependence on logistics), variability of operating Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for results and allocations between customer classes, and the commercial development of markets reconciliations of historical non-GAAP measures to comparable GAAP measures and the for our products to customers in academia, pharma, applied testing and molecular diagnostics; definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non- changing relationships with customers, suppliers and strategic partners; competition; rapid or GAAP financial measures to the corresponding GAAP measures due to the high variability and unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including difficulty in making accurate forecasts and projections that are impacted by future decisions and factors such as general economic conditions, the level and timing of customers' funding, budgets actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to and other factors); our ability to obtain regulatory approval of our products; technological the corresponding GAAP measures are not available without unreasonable effort. However, the advances of our competitors and related legal disputes; difficulties in successfully adapting actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN results. to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward- looking statements as a result of new information or future events or developments unless and to the extent required by law. Sample to Insight 2019 Analyst & Investor Day 2
Bioinformatics market offers dynamic growth opportunities Our customers Total addressable market Key trends • Bioinformatics industry transition Clinical testing Evolution of regulatory landscape accelerating entry into the mainstream of healthcare IT QIAGEN market share: ~20% Decision support for • Aggregation and analysis of big data improved outcomes Explosion of research and clinical data breaking traditional approaches to data analysis • Emergence of data science ~$500 m Discovery Machine Learning and Artificial Intelligence to ~+10% CAGR exploit rapidly growing volumes of big data Deep insights into disease biology ~$350 m • Clinical data integration with genomics Provide context to improve outcomes and Microbiome research drive genomic-guided real world insights Pharma and clinical trials Digital transformation of trials with real-world 2019 2023 evidence estimate Sample to Insight 2019 Analyst & Investor Day 3
Building the best suite of content-driven analytics Bioinformatics sales trends (1) Discovery informatics Curated research data and knowledge bases with #1 2019-2023 target: integrated analysis and interpretation solutions ~+10-15% CER CAGR 2012-2018: ~+10-15% CER CAGR ~$65 m Clinical testing informatics ~$48 m ~$41 m Knowledge bases of clinically relevant variants #1 for hereditary and somatic assays with QCI reporting ~$0 m 2012 2014 2016 2018 2023 mid-term target Genomic-based content 2018 sales by region and customer class Unique digital assets compiled over 20 years, #1 curated knowledge of real-world data and experience Molecular Diagnostics Asia-Pacific / Japan (~9,000 users) ~20% ~20% EMEA Americas Life Sciences ~55% (~80,000 users) ~25% ~80% (1) Sales are distributed between QIAGEN’s Life Sciences and Molecular Diagnostics customer classes Sample to Insight 2019 Analyst & Investor Day 4
Strategy: Expand leadership in data analysis, interpretation and content Build on genomics leadership Help customers achieve fast and actionable insights The partner of Expand our datasets choice to get Combine our curated and public data with secure access to patient datasets actionable insights from complex Enhance data mining molecular and Discover new connections in data to help support better patient outcomes real-world data Develop customer base Build on our current strengths to increase QIAGEN’s overall value contribution Sample to Insight 2019 Analyst & Investor Day 5
QIAGEN is the partner of choice for actionable insights from molecular and real world data Curated literature Guidelines Protocols Patient data Drug labels Ontology + Models Curated Big Data Genomic datasets Sample to Insight 2019 Analyst & Investor Day 6
Build on genomics leadership: Help customers achieve fast and actionable insights 2016 2019 Sample to Insight 2019 Analyst & Investor Day 7
Case study: One QIAGEN order to receive complete Sample to Insight NGS solution QIAseq DNA Panels CLC Genomics QCI-Interpret and Index Kit Workbench BIOLOGICAL VALUABLE SAMPLE MOLECULAR INSIGHTS Easy to buy Superior analysis results Powerful and easy to use integrated solution *Products are intended for molecular biology applications. Research use only. Sample to Insight 2019 Analyst & Investor Day 8
Case study: QIAGEN Clinical Insight (QCI) as preferred partner for national programs Multi-year partnership as preferred vendor Multi-year partnership to deliver custom Multi-year partnership for molecular oncology for Genomics England to analyze 5 million NGS patient data interpretation for genetic and oncogenetic screening data in Japan’s genomes in 5 years for genetic disorders markers for predispositions landmark program with NGS testing Dr. Augusto Rendon, Director of Bioinformatics and Dr. Asmaa Al Thani, Chair of Qatar Genome and Dr. Hiroyuki Mano, Director of C-CAT at Japan’s Genomics England: Board Vice Chairperson of Qatar Biobank: National Cancer Center (NCC): “NGS is a valuable tool for diagnosing and “The mission of our Genome Programme is to “C-CAT and our network of hospitals will use the suggesting potential treatment approaches, but it is create a healthier population for generations to QCI solution because of the breadth and depth of critical for healthcare providers to be able to come... We selected QIAGEN as our partner for its professionally curated knowledge base, the interpret NGS data in the context of the vast body genomic interpretation due to their leadership in ability to match patients with approved treatments of knowledge from research and clinical bioinformatics, including a vast knowledge base or clinical trials and QIAGEN’s customization of its experience.” that connects sequencing data with the latest QCI solution for C-CAT’s specific needs.” research to improve clinical outcomes.” Sample to Insight 2019 Analyst & Investor Day 9
Expand our datasets: Combine our curated and public data with patient datasets Curated literature Curated literature Guidelines Guidelines Protocols Protocols Patient data Patient data Drug labels Drug labels Ontology Ontology + + Models Models Curated Big Data Curated Big Data Genomic datasets Genomic datasets Sample to Insight 2019 Analyst & Investor Day 10
Recommend
More recommend
